As per the WHO statistics, the global prevalence of diabetes, increased to 8.5% in adults over the age of 18 in the year 2014 from 4.7% in the year 1980. This rising prevalence of chronic diseases has led to an increase in the demands for improved treatments and diagnostic services. For the treatment of these types of diseases, various novel ways to administer drugs have been developed such as needle-free injectors, autoinjectors, pen injectors, and pre-filled syringes. According to the latest market intelligence report by BIS Research titled, ‘Global Injectable Drug Delivery Market- Analysis and Forecast (2018-2025),’ the market was estimated at $16.73 billion in 2016. The market for drug injectable is anticipated to grow over $37.47 billion by the year 2025. This significant growth is majorly attributed to the increase in the chronic diseases along with the rise in the geriatric population.

The injectables drug devices are being used for the administration of various medications especially for the biological products and proteins, such as insulin. These devices provide a safe and efficient method of drug delivery along with the advantage of self -administration. The market for drug delivery system is expected to reach a niche level by 2025 owing to the technological developments, rising demands in the developing nations, and rising prevalence of autoimmune and chronic diseases. The rise in the developments and commercialization of biologics for various therapeutic indications is another factor leading to the high demands for injectable drug delivery systems, globally. The market for injectable drug delivery system can be segmented into devices, end-users, the route for administration, and geographical regions.

Geographically, the largest contributor to the growth of the global injectable drug delivery system was Europe in the year 2016. Owing to the presence of supportive governmental regulations and technologically advanced healthcare infrastructure were the reasons for the dominance of Europe. In terms of revenue generation, Europe is followed by North America. The emerging market of the Rest of the World (RoW) is expected to register the highest CAGR during the forecast period. The significant growth is owing to the rising healthcare expenditure and increasing patient awareness in RoW. Based on the end-users, the global market for injectable drug delivery system can be segmented into hospitals, clinics, home care, ambulatory centers and others. Moreover, the market for home-based care is expected to reach $13.04 billion by the year 2025.

Based on the devices, the global market for injectable drug delivery system can be segmented into needle-free technology, auto-injectors, and pen injectors. Earlier needle-based injections were used. However, these had certain limitations. To overcome the same, needle-free technology for injections was developed.  Based on the route of administration, the market can be segmented into intravenous, subcutaneous, intraperitoneal, and intramuscular. The prominent market players of the market for injectable drug delivery system are Antares Pharma, Becton Dickinson and Company, Baxter International AG, Elcam Medical, Sanofi Gerresheimer AG, and Schott SAG, among others.

BIS Research has conducted extensive research on the global injectable drug delivery market and compiled the observation and insight in this report. The market intelligence report aims at providing an in-depth analysis of the key development strategies, marketing strategies and market trend dynamics which include drivers, restraints, and opportunities prevailing in the industry.

For further queries, please write to us at sales@bisresearch.com or call us at: +1 650 228 0182.